At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis
In Brief
A Phase 2 clinical trial evaluating cyclophosphamide, dexamethasone, and 1 other intervention for Multiple Myeloma and Plasma Cell Neoplasm. Completed, enrolled 35 participants across 3 sites.
Detailed Summary
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop plasma cells from growing. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with cyclophosphamide and dexamethasone may be an effective treatment for primary systemic amyloidosis. PURPOSE: This phase II trial is studying how well giving lenalidomide together with cyclophosphamide and dexamethasone works in treating patients with primary systemic amyloidosis.
Study Details
Timeline
Interventions
300 mg/m\^2 days 1, 8 \& 15 of a 28 day cycle taken orally with food
40 mg weekly taken orally
15 mg daily days 1-21 of a 28 day cycle taken orally with food